Journal of Shanghai Jiao Tong University (Medical Science) ›› 2025, Vol. 45 ›› Issue (2): 194-203.doi: 10.3969/j.issn.1674-8115.2025.02.008
• Evidence-based medicine • Previous Articles
ZHU Hanjing1(), GUO Yan1, YIN Hongfan2, WANG Beibei1, XIE Juan1, YANG Yan1(
)
Received:
2024-04-12
Accepted:
2024-08-19
Online:
2025-02-28
Published:
2025-02-28
Contact:
YANG Yan
E-mail:zhu_hanjing@163.com;renji_yy@126.com
Supported by:
CLC Number:
ZHU Hanjing, GUO Yan, YIN Hongfan, WANG Beibei, XIE Juan, YANG Yan. Best evidence summary of weight management in patients undergoing endocrine therapy for prostate cancer[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 194-203.
Procedure | Search strategy |
---|---|
#1 | prostate neoplasm[MeSH] OR prostate cancer[Title/Abstract] OR PCa[Title/Abstract] OR prostate tumor[Title/Abstract] OR prostate neoplasms[Title/Abstract] |
#2 | endocrinotherapy[Title/Abstract] OR androgen deprivation therapy[Title/Abstract] OR anti androgen[Title/Abstract] OR ADT[Title/Abstract] OR anti androgenic therapy[Title/Abstract] |
#3 | nutrition[Title/Abstract] OR dietary[Title/Abstract] OR diet[MeSH] OR weight[Title/Abstract] OR nutritional[Title/Abstract] OR food[MeSH] |
#4 | #1 AND #2 AND #3 |
Tab 1 Retrieval strategy in PubMed
Procedure | Search strategy |
---|---|
#1 | prostate neoplasm[MeSH] OR prostate cancer[Title/Abstract] OR PCa[Title/Abstract] OR prostate tumor[Title/Abstract] OR prostate neoplasms[Title/Abstract] |
#2 | endocrinotherapy[Title/Abstract] OR androgen deprivation therapy[Title/Abstract] OR anti androgen[Title/Abstract] OR ADT[Title/Abstract] OR anti androgenic therapy[Title/Abstract] |
#3 | nutrition[Title/Abstract] OR dietary[Title/Abstract] OR diet[MeSH] OR weight[Title/Abstract] OR nutritional[Title/Abstract] OR food[MeSH] |
#4 | #1 AND #2 AND #3 |
Included literature | Literature type | Language | Research theme | Publication year |
---|---|---|---|---|
GONG, et al[ | Evidence summary | Chinese | Non-pharmacological management of osteoporosis in androgen-deprived patients with prostate cancer | 2022 |
FANKHAUSER, et al[ | Evidence summary | English | Indications and complications of androgen deprivation therapy | 2020 |
BARNES, et al[ | Guideline | English | Weight management in prostate cancer patients undergoing androgen deprivation therapy | 2019 |
OWEN, et al[ | Guideline | English | Lifestyle management in patients undergoing androgen deprivation therapy for prostate cancer | 2017 |
NOONAN, et al[ | Guideline | English | Care for prostate cancer survivors | 2016 |
RESNICK, et al[ | Guideline | English | Prostate cancer survival care guidelines | 2015 |
Chinese Society of Nutritional Oncology, et al[ | Expert consensus | Chinese | Nutritional therapy for prostate cancer patients | 2021 |
Urological Health Promotion Branch of China International Exchange and Promotion Association for Medical and Health Care, et al[ | Expert consensus | Chinese | Consensus on the safety of classical endocrine therapy for prostate cancer | 2018 |
GROSSMANN, et al[ | Expert consensus | English | Skeletal and metabolic management in prostate cancer patients treated with androgen deprivation | 2011 |
FAN, et al[ | RCT | Chinese | Effects of multi-dimensional family survival programs on health-related quality of life in patients undergoing endocrine therapy | 2021 |
GREASLEY[ | RCT | English | Lifestyle intervention in castrated prostate cancer patients | 2018 |
BULTIJNCK, et al[ | quasi-RCT | English | Evidence-based strategies to improve side effects of androgen deprivation therapy in prostate cancer patients | 2018 |
Tab 2 Basic information of included studies (n=12)
Included literature | Literature type | Language | Research theme | Publication year |
---|---|---|---|---|
GONG, et al[ | Evidence summary | Chinese | Non-pharmacological management of osteoporosis in androgen-deprived patients with prostate cancer | 2022 |
FANKHAUSER, et al[ | Evidence summary | English | Indications and complications of androgen deprivation therapy | 2020 |
BARNES, et al[ | Guideline | English | Weight management in prostate cancer patients undergoing androgen deprivation therapy | 2019 |
OWEN, et al[ | Guideline | English | Lifestyle management in patients undergoing androgen deprivation therapy for prostate cancer | 2017 |
NOONAN, et al[ | Guideline | English | Care for prostate cancer survivors | 2016 |
RESNICK, et al[ | Guideline | English | Prostate cancer survival care guidelines | 2015 |
Chinese Society of Nutritional Oncology, et al[ | Expert consensus | Chinese | Nutritional therapy for prostate cancer patients | 2021 |
Urological Health Promotion Branch of China International Exchange and Promotion Association for Medical and Health Care, et al[ | Expert consensus | Chinese | Consensus on the safety of classical endocrine therapy for prostate cancer | 2018 |
GROSSMANN, et al[ | Expert consensus | English | Skeletal and metabolic management in prostate cancer patients treated with androgen deprivation | 2011 |
FAN, et al[ | RCT | Chinese | Effects of multi-dimensional family survival programs on health-related quality of life in patients undergoing endocrine therapy | 2021 |
GREASLEY[ | RCT | English | Lifestyle intervention in castrated prostate cancer patients | 2018 |
BULTIJNCK, et al[ | quasi-RCT | English | Evidence-based strategies to improve side effects of androgen deprivation therapy in prostate cancer patients | 2018 |
Included literature | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Item 10 |
---|---|---|---|---|---|---|---|---|---|---|
GONG, et al[ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
FANKHAUSER, et al[ | Yes | Yes | No | Partly yes | No | Yes | Yes | Yes | Yes | Yes |
Tab 3 Quality evaluation of included evidence summaries (n=2)
Included literature | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Item 7 | Item 8 | Item 9 | Item 10 |
---|---|---|---|---|---|---|---|---|---|---|
GONG, et al[ | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
FANKHAUSER, et al[ | Yes | Yes | No | Partly yes | No | Yes | Yes | Yes | Yes | Yes |
Included literature | Standardization percentage by field/% | Number of fields with a standardization percentage ≥60%/n | Number of fields with a standardization percentage ≥30%/n | Recommendation level | |||||
---|---|---|---|---|---|---|---|---|---|
Scope and purpose | Stakeholder involvement | Rigor of development | Clarity of presentation | Applicability | Editorial independence | ||||
NOONAN, et al[ | 94.44 | 83.33 | 58.33 | 83.33 | 62.50 | 75.00 | 5 | 6 | B |
RESNICK, et al[ | 100.00 | 88.89 | 85.41 | 88.89 | 70.83 | 66.67 | 6 | 6 | A |
BARNES, et al[ | 100.00 | 94.44 | 91.67 | 94.44 | 87.50 | 91.67 | 6 | 6 | A |
OWEN, et al[ | 100.00 | 94.44 | 93.75 | 83.33 | 79.17 | 75.00 | 6 | 6 | A |
Tab 4 Quality evaluation of included guidelines (n=4)
Included literature | Standardization percentage by field/% | Number of fields with a standardization percentage ≥60%/n | Number of fields with a standardization percentage ≥30%/n | Recommendation level | |||||
---|---|---|---|---|---|---|---|---|---|
Scope and purpose | Stakeholder involvement | Rigor of development | Clarity of presentation | Applicability | Editorial independence | ||||
NOONAN, et al[ | 94.44 | 83.33 | 58.33 | 83.33 | 62.50 | 75.00 | 5 | 6 | B |
RESNICK, et al[ | 100.00 | 88.89 | 85.41 | 88.89 | 70.83 | 66.67 | 6 | 6 | A |
BARNES, et al[ | 100.00 | 94.44 | 91.67 | 94.44 | 87.50 | 91.67 | 6 | 6 | A |
OWEN, et al[ | 100.00 | 94.44 | 93.75 | 83.33 | 79.17 | 75.00 | 6 | 6 | A |
Included literature | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Recommendation level |
---|---|---|---|---|---|---|---|
Chinese Society of Nutritional Oncology, et al[ | Yes | Yes | Yes | Yes | Yes | Unclear | A |
Urological Health Promotion Branch of China International Exchange and Promotion Association for Medical and Health Care, et al[ | No | Yes | Yes | Yes | Yes | Unclear | B |
GROSSMANN, et al[ | Yes | Yes | Yes | Yes | Yes | No | A |
Tab 5 Quality evaluation of included expert consensus (n=3)
Included literature | Item 1 | Item 2 | Item 3 | Item 4 | Item 5 | Item 6 | Recommendation level |
---|---|---|---|---|---|---|---|
Chinese Society of Nutritional Oncology, et al[ | Yes | Yes | Yes | Yes | Yes | Unclear | A |
Urological Health Promotion Branch of China International Exchange and Promotion Association for Medical and Health Care, et al[ | No | Yes | Yes | Yes | Yes | Unclear | B |
GROSSMANN, et al[ | Yes | Yes | Yes | Yes | Yes | No | A |
1 | SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. |
2 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. |
3 | 赵劲歌, 曾浩. 2020年欧洲泌尿外科学会(EAU)前列腺癌指南更新荟萃与解读[J]. 现代泌尿外科杂志, 2020, 25(9): 832-836, 841. |
ZHAO J G, ZENG H. European Association of Urology (EAU) Guidelines on Prostate Cancer 2020: Update and interpretation[J]. Journal of Modern Urology, 2020, 25(9): 832-836, 841. | |
4 | ODERDA M, BERTETTO O, BARBERA G, et al. Appropriateness and complications of androgen deprivation therapy for prostate cancer: can we do better? A retrospective observational analysis from a referral center[J]. Urologia, 2023, 90(1): 100-108. |
5 | NGUYEN P L, ALIBHAI S M H, BASARIA S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them[J]. Eur Urol, 2015, 67(5): 825-836. |
6 | STØYTEN M, KNUTSEN T, STIKBAKKE E, et al. Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study[J]. Acta Oncol, 2024, 63: 154-163. |
7 | 朱政, 胡雁, 邢唯杰, 等. 不同类型循证问题的构成[J]. 护士进修杂志, 2017, 32(21): 1991-1994. |
ZHU Z, HU Y, XING W J, et al. The composition of different types of evidence-based problems[J]. Journal of Nurses Training, 2017, 32(21): 1991-1994. | |
8 | ALPER B S, BRIAN HAYNES R. EBHC pyramid 5.0 for accessing preappraised evidence and guidance[J]. Evid Based Med, 2016, 21(4): 123-125. |
9 | FOSTER M J, SHURTZ S. Making the critical appraisal for summaries of evidence (CASE) for evidence-based medicine (EBM): critical appraisal of summaries of evidence[J]. J Med Libr Assoc, 2013, 101(3): 192-198. |
10 | 韦当, 王聪尧, 肖晓娟, 等. 指南研究与评价(AGREEⅡ)工具实例解读[J]. 中国循证儿科杂志, 2013, 8(4): 316-319. |
WEI D, WANG C Y, XIAO X J, et al. Interpretation of Appraisal of Guidelines for Research & Evaluation Ⅱ (AGREEⅡ) with examples[J]. Chinese Journal of Evidence-Based Pediatrics, 2013, 8(4): 316-319. | |
11 | 陈红丽, 张戈, 赵青, 等. 近10年国内护理专家共识文献质量评价与分析[J]. 中国护理管理, 2020, 20(3): 399-406. |
CHEN H L, ZHANG G, ZHAO Q, et al. Quality evaluation and analysis of domestic nursing experts' consensus literature in the past ten years[J]. Chinese Nursing Management, 2020, 20(3): 399-406. | |
12 | 顾莺, 张慧文, 周英凤, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具: 系统评价的方法学质量评价[J]. 护士进修杂志, 2018, 33(8): 701-703. |
GU Y, ZHANG H W, ZHOU Y F, et al. JBI evidence-based health center's quality assessment tool for different types of research: the quality evaluation of diagnostic and economic evaluation[J]. Journal of Nurses Training, 2018, 33(8): 701-703. | |
13 | 马捷, 刘莹, 钟来平, 等. Jadad量表与Cochrane偏倚风险评估工具在随机对照试验质量评价中的应用与比较[J]. 中国口腔颌面外科杂志, 2012, 10(5): 417-422. |
MA J, LIU Y, ZHONG L P, et al. Comparison between Jadad scale and Cochrane collaboration's tool for assessing risk of bias on the quality and risk of bias evaluation in randomized controlled trials[J]. China Journal of Oral and Maxillofacial Surgery, 2012, 10(5): 417-422. | |
14 | 周英凤, 顾莺, 胡雁, 等. JBI循证卫生保健中心关于不同类型研究的质量评价工具: 干预性研究的质量评价(一)[J]. 护士进修杂志, 2018, 33(1): 24-26. |
ZHOU Y F, GU Y, HU Y, et al. Quality assessment tool of different types of research for JBI evidence based health care: quality evaluation of intervention study[J]. Journal of Nurses Training, 2018, 33(1): 24-26. | |
15 | 王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11): 964-967. |
WANG C Y, HU Y. JBI evidence pre-classification and evidence rank system (2014 edition)[J]. Journal of Nurses Training, 2015, 30(11): 964-967. | |
16 | 龚苗, 邵海燕, 屠耀芬, 等. 前列腺癌雄激素剥夺治疗患者骨质疏松非药物管理的最佳证据总结[J]. 中华现代护理杂志, 2022, 28(34): 4732-4738. |
GONG M, SHAO H Y, TU Y F, et al. Best evidence summary of non-pharmacological management of osteoporosis in patients with androgen deprivation therapy for prostate cancer[J]. Chinese Journal of Modern Nursing, 2022, 28(34): 4732-4738. | |
17 | FANKHAUSER C D, WETTSTEIN M S, REINHARDT M, et al. Indications and complications of androgen deprivation therapy[J]. Semin Oncol Nurs, 2020, 36(4): 151042. |
18 | BARNES K A, BALL L E, GALVÃO D A, et al. Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence?[J]. Prostate Cancer Prostatic Dis, 2019, 22(2): 221-234. |
19 | OWEN P J, DALY R M, LIVINGSTON P M, et al. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update[J]. Prostate Cancer Prostatic Dis, 2017, 20(2): 137-145. |
20 | NOONAN E M, FARRELL T W. Primary care of the prostate cancer survivor[J]. Am Fam Physician, 2016, 93(9): 764-770. |
21 | RESNICK M J, LACCHETTI C, BERGMAN J, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement[J]. J Clin Oncol, 2015, 33(9): 1078-1085. |
22 | 中国抗癌协会肿瘤营养专业委员会, 中华医学会肠外肠内营养学分会. 肿瘤相关性腹泻的营养治疗专家共识[J]. 肿瘤代谢与营养电子杂志, 2021, 8(5): 503-507. |
Chinese Society of Nutritional Oncology, Chinese Society for Parenteral and Enteral Nutrition. Expert opinion on nutritional treatment for patients with prostate cancer[J]. Electronic Journal of Metabolism and Nutrition of Cancer, 2021, 8(5): 503-507. | |
23 | 中国医促会泌尿健康促进分会, 中国研究型医院学会泌尿外科学专业委员会. 前列腺癌经典内分泌治疗安全共识[J]. 现代泌尿外科杂志, 2018, 23(4): 248-258. |
Urological Health Promotion Branch of China International Exchange and Promotion Association for Medical and Health Care, Urological Surgery Committee of Chinese Research Hospital Association. Consensus on the safety of classical endocrine therapy for prostate cancer[J]. Journal of Modern Urology, 2018, 23(4): 248-258. | |
24 | GROSSMANN M, HAMILTON E J, GILFILLAN C, et al. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy[J]. Med J Aust, 2011, 194(6): 301-306. |
25 | 樊荣, 蒋玉梅, 白晓静, 等. 基于家庭多维度生存计划对内分泌治疗的老年前列腺癌患者健康相关生活质量的影响[J]. 护士进修杂志, 2021, 36(14): 1323-1327. |
FAN R, JIANG Y M, BAI X J, et al. Effects of a family-based multidimensional survival plan on health-related quality of life in elderly patients with prostate cancer undergoing endocrine therapy[J]. Journal of Nurses Training, 2021, 36(14): 1323-1327. | |
26 | GREASLEY R. A lifestyle intervention to improve outcomes in men with castrate-resistant prostate cancer[D]. Sheffield: Sheffield Hallam University, 2018. |
27 | BULTIJNCK R, VAN DE CAVEYE I, RAMMANT E, et al. Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer[J]. BJU Int, 2018, 121(4): 610-618. |
28 | LIU X, YU C, BI Y, et al. Trends and age-period-cohort effect on incidence and mortality of prostate cancer from 1990 to 2017 in China[J]. Public Health, 2019, 172: 70-80. |
29 | MITSUZUKA K, ARAI Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy[J]. Int J Urol, 2018, 25(1): 45-53. |
30 | HARRINGTON J M, SCHWENKE D C, EPSTEIN D R, et al. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer[J]. Oncol Nurs Forum, 2014, 41(1): 21-29. |
31 | 朱涵菁, 殷弘凡, 尤思洁, 等. 前列腺癌患者内分泌治疗相关不良反应的潜在剖面分析[J]. 上海交通大学学报(医学版), 2023, 43(9): 1186-1193. |
ZHU H J, YIN H F, YOU S J, et al. Latent profile analysis of adverse effects associated with endocrine therapy in prostate cancer patients based on the theory of unpleasant symptoms[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(9): 1186-1193. | |
32 | ARENDS J, BACHMANN P, BARACOS V, et al. ESPEN guidelines on nutrition in cancer patients[J]. Clin Nutr, 2017, 36(1): 11-48. |
33 | 马丽娜, 吉彤, 李海龙, 等. 老年人营养不良多学科决策模式中国专家共识 (2023)[J]. 中国临床保健杂志, 2023, 26(4): 433-445. |
MA L N, JI T, LI H L, et al. Chinese expert consensus on multidisciplinary decision models for the elderly with malnutrition (2023)[J]. Chinese Journal of Clinical Healthcare, 2023, 26(4): 433-445. | |
34 | DELEGGE M H, KELLY A T. State of nutrition support teams[J]. Nutr Clin Pract, 2013, 28(6): 691-697. |
35 | DELICHATSIOS H K, PITTAS A G. Integrating nutrition education into clinical practice[J]. Nestle Nutr Inst Workshop Ser, 2019, 92: 171-182. |
36 | WILSON R L, TAAFFE D R, NEWTON R U, et al. Obesity and prostate cancer: a narrative review[J]. Crit Rev Oncol Hematol, 2022, 169: 103543. |
37 | GUPTA D, LEE CHUY K, YANG J C, et al. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer[J]. J Oncol Pract, 2018, 14(10): 580-587. |
38 | XU J L, HOOVER R L, WOODARD N, et al. A systematic review of dietary interventions for cancer survivors and their families or caregivers[J]. Nutrients, 2023, 16(1): 56. |
39 | AUNE D, GIOVANNUCCI E, BOFFETTA P, et al. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality: a systematic review and dose-response meta-analysis of prospective studies[J]. Int J Epidemiol, 2017, 46(3): 1029-1056. |
40 | SAHA A, KOLONIN M G, DIGIOVANNI J. Obesity and prostate cancer: microenvironmental roles of adipose tissue[J]. Nat Rev Urol, 2023, 20(10): 579-596. |
41 | GÓMEZ-APARICIO M A, LÓPEZ-CAMPOS F, PELARI-MICI L, et al. Bone health and therapeutic agents in advanced prostate cancer[J]. Front Biosci (Landmark Ed), 2022, 27(1): 34. |
42 | RODRÍGUEZ-CAÑAMERO S, COBO-CUENCA A I, CARMONA-TORRES J M, et al. Impact of physical exercise in advanced-stage cancer patients: systematic review and meta-analysis[J]. Cancer Med, 2022, 11(19): 3714-3727. |
43 | HART N H, CRAWFORD-WILLIAMS F, CRICHTON M, et al. Unmet supportive care needs of people with advanced cancer and their caregivers: a systematic scoping review[J]. Crit Rev Oncol Hematol, 2022, 176: 103728. |
44 | WU Z M, NGUYEN N H, WANG D W, et al. Social connectedness and mortality after prostate cancer diagnosis: a prospective cohort study[J]. Int J Cancer, 2020, 147(3): 766-776. |
45 | RAMIREZ A G, CHOI B Y, MUNOZ E, et al. Assessing the effect of patient navigator assistance for psychosocial support services on health-related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors[J]. Cancer, 2020, 126(5): 1112-1123. |
[1] | YANG Liling, ZHAN Sha, XUE Xiaoyan, CHEN Kai, LIU Qing, WANG Li, WANG Yiyi, WU Meng, LU Qunfeng. Development of indicators and analysis of barriers for assessment and prevention of cutaneous graft-versus-host disease after haematopoietic stem cell transplantation in children [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(12): 1552-1560. |
[2] | LI Yan, JIANG Yan, KANG Qiongfang, LU Qunfeng. Summary of the best evidence summary on prevention strategies for diaper dermatitis in infants [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(3): 357-363. |
[3] | ZHU Yin-jie, WANG Yan-qing, PAN Jia-hua, DONG Bai-jun, XUE Wei. PET/CT for guidance of lymphadenectomy of high-risk prostate cancer in patients with chronic lymphocytic leukemia: 1 case report [J]. , 2019, 39(4): 440-. |
Viewed | ||||||||||||||||||||||||||||||||||||||||||||||||||
Full text 81
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Abstract 87
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||